Steven E. Finkelstein, MD, discusses radiobiologic concepts of different fractionation schedules for prostate cancer. He also reviews a 2018 guideline for hypofractionated external beam radiotherapy (EBRT) to treat localized prostate cancer, and its ramifications for the future of radiation oncology.Read More
Steven E. Finkelstein, MD, FACRO
[types usermeta='affiliation' user_is_author='true'][/types]
[types usermeta='location' user_is_author='true'][/types]
Steven E. Finkelstein, MD, FACRO, currently serves as a Co-Chair on the NRG Immunotherapy Committee, Co-Chair of the 2018-2019 ACRO Scientific Program Committee, and is the Chair of the SWOG Radiation STG Committee. He also serves on the Board of Chancellors and is the Chair of Education Committee for ACRO, Editor-in-Chief for Contemporary Radiation Oncology, and Editor of ASCO Publications. Dr. Finkelstein has been National Director of Translational Research Consortium (TRC), the cutting-edge therapy arm of 21st Century Oncology in Scottsdale, Arizona. Dr. Finkelstein is responsible for expanding patient access to advanced cancer care. Inspired by his grandmother, a cancer patient, he became a dedicated cancer surgeon who found that radiation therapy could sometimes do for his patients what surgery could not. Dr. Finkelstein received his medical degree from the University of Michigan Medical School. He served a residency in General Surgery at Washington University in Saint Louis, Missouri, and was Chief Resident in Radiation Oncology at the Moffitt Cancer Center in Tampa, Florida. Dr. Finkelstein also served fellowships in Biologic Immunotherapy Clinical Cancer and Surgical Oncology at the Surgery Branch of the National Cancer Institute, NIH in Bethesda, Maryland. He is a member of the American College of Radiation Oncology, American Medical Association, American Society of Clinical Oncology, American Society for Therapeutic Radiology and Oncology, the Radiological Society of North America, and the Radiation Therapy Oncology Group.
Articles by Steven E. Finkelstein, MD, FACRO
Posted by Steven E. Finkelstein, MD, FACRO | Oct 2018
Steven E. Finkelstein, MD, FACRO, provides a brief update on hydrogel spacers to minimize toxicity to the rectum from prostate radiotherapy, as well as a novel hydrogel technology for multiple disease sites.Read More
Posted by Steven E. Finkelstein, MD, FACRO | Apr 2016
Dr. Finkelstein presented at the 26th International Prostate Cancer Update on Friday, January 22,...Read More
Posted by Steven E. Finkelstein, MD, FACRO | Feb 2016
Dr. Steven E. Finkelstein spoke at the 24th annual Perspectives in Urology Point • Counterpoint...Read More
State of the Art Connection Between Immunotherapy and Radiation Therapy: Where We Are Now and Where We Are Going?
Posted by Steven E. Finkelstein, MD, FACRO | Sep 2015
Dr. Steven E. Finkelstein spoke at the 16th Future Directions in Urology Symposium on Monday, August 10, 2015 on “State of the Art Connection Between Immunotherapy and Radiation Therapy: Where We Are Now and Where We Are...Read More